Aachen, Germany (OTE) – – Grünenthal acquired Kyowa Kirin
International’s 49% stake in
‚Grünenthal Meds‘, a joint venture formed in 2023 to market the
established medicines portfolio from Kyowa Kirin International.
– Through this acquisition, Grünenthal assumes the sole
responsibility of a portfolio comprising 12 brands across six
therapeutic areas and >60 markets.
Grünenthal today announced that it has acquired Kyowa Kirin
International’s 49% stake in ‚Grünenthal Meds‘, taking full ownership
of the company formed through a joint venture and its portfolio of
established medicines.
‚Grünenthal Meds‘ was created in 2023 as a joint venture between
Grünenthal (51%) and Kyowa Kirin International (49%), the EMEA
business of the Japanese-based global specialty pharmaceutical
company. Over the past three years, the joint venture operated as a
separate entity with eight affiliates, managing a growing EUR170
million portfolio of 12 established brands across six therapeutic
areas and more than 60 markets. Key products included Abstral® and
PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (
Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and
vitamin D3) for osteoporosis.
„Thanks to the outstanding expertise and commitment of our teams
in Grünenthal and Grünenthal Meds, we were able to manage this
complex portfolio across regions, generate growth, and create
synergies with our infrastructure – all while executing a staggered
integration approach,“ said Gabriel Baertschi, Chief Executive
Officer of Grünenthal. „The integration of ‚Grünenthal Meds‘ confirms
our leading capabilities in deal execution and integration and
successfully concludes one of the most complex undertakings of our M&
A journey, which stretched far beyond a merger or asset deal.“
The ongoing integration of ‚Grünenthal Meds‘ includes the
transfer of more than 200 marketing authorisations, approximately 150
product-country combinations, and several tech transfers in close
alignment with a broad landscape of partners and contract
manufacturing organisations. Grünenthal expects to complete the
integration by June 2026. At this point, Grünenthal will
commercialise the ‚Grünenthal Meds‘ portfolio through Grünenthal
affiliates in major European markets and via international partners
in additional territories.
The acquisition of ‚Grünenthal Meds‘ is based on an option agreed
with Kyowa Kirin International at the beginning of the joint venture
collaboration. The transaction supports Grünenthal’s long-term growth
strategy. Since 2017, Grünenthal has closed successful acquisitions
with a total expected deal value of more than EUR2.3 billion,
strengthening and diversifying its portfolio while leveraging
synergies across manufacturing, supply chain, logistics, and
commercial operations.
About Grünenthal
Grünenthal is a global leader in pain management and related
diseases. As a science-based, fully integrated pharmaceutical
company, we have a long track record of bringing innovative
treatments and state-of-the-art technologies to patients worldwide.
Our purpose is to change lives for the better – and innovation is our
passion. We focus all our activities and efforts on working towards
our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has
affiliates in 28 countries across Europe, Latin America, and the U.S.
Our products are available in approx. 100 countries. In 2024,
Grünenthal employed around 4,300 people and achieved revenues of
EUR1.8 billion.
More information: www.grunenthal.com
Follow us on LinkedIn & Instagram
Digital press kit: http://www.ots.at/pressemappe/DE118252/aom